Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

Eleanor L. Olvey, Karen MacDonald, Ivo L Abraham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalPharmaceuticals Policy and Law
Volume14
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Comparative Effectiveness Research
Legislation
Uncertainty
Cost-Benefit Analysis
Economics
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Comparative effectiveness research (CER)
  • effectiveness
  • health technology assessment
  • outcomes
  • pharmacoeconomics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

@article{70befe7f6ec348f8a2ad8d0aef6b9aa9,
title = "Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness",
abstract = "Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.",
keywords = "Comparative effectiveness research (CER), effectiveness, health technology assessment, outcomes, pharmacoeconomics",
author = "Olvey, {Eleanor L.} and Karen MacDonald and Abraham, {Ivo L}",
year = "2012",
doi = "10.3233/PPL-2011-0340",
language = "English (US)",
volume = "14",
pages = "27--35",
journal = "Pharmaceuticals Policy and Law",
issn = "1389-2827",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Comparative effectiveness research

T2 - The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

AU - Olvey, Eleanor L.

AU - MacDonald, Karen

AU - Abraham, Ivo L

PY - 2012

Y1 - 2012

N2 - Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

AB - Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

KW - Comparative effectiveness research (CER)

KW - effectiveness

KW - health technology assessment

KW - outcomes

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84856823973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856823973&partnerID=8YFLogxK

U2 - 10.3233/PPL-2011-0340

DO - 10.3233/PPL-2011-0340

M3 - Article

AN - SCOPUS:84856823973

VL - 14

SP - 27

EP - 35

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 1

ER -